Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 11Nivolumab 6fludarabine phosphate 5fludarabine 5Paclitaxel 5Cyclophosphamide 5Cisplatin 5Cetuximab 5Carboplatin 5atezolizumab 4Specimen Handling 4Pemetrexed 4Docetaxel 4Bevacizumab 4durvalumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3venetoclax 2temsirolimus 2niraparib 2ibrutinib 2enzalutamide 2encorafenib 2binimetinib 2Trastuzumab 2Taxes 2Standard of Care 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interleukin-2 × 30 days × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡